Clinical trial Recruiting at 1 site Phase 2 Interventional Ages 50 and up Women only

Equol and vascular function in women with CKD

Official title: Equol Supplementation for Improving Vascular Function in Postmenopausal Women With CKD

Run by University of Colorado, Denver · NCT07194590 · Data updated 2026-11-12

This study tests whether taking equol for 12 weeks improves vascular function in postmenopausal women with chronic kidney disease.

Quick facts

PhasePhase 2
Study typeInterventional
Ages50 Years and up
SexWomen only
Enrollment74 (estimated)
SponsorUniversity of Colorado, Denver
Academic / other
Locations1 site (Aurora, Colorado)
StatusRecruiting
StartedFebruary 19, 2026
Main results expectedNovember 30, 2030
Study endsNovember 30, 2030
Registry record updatedJune 2, 2026
Trial IDNCT07194590 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Postmenopausal women aged 50 or older with CKD stage 3–4 (eGFR 15–59), stable renal function, and low soy intake.

Probably not a fit

Individuals with advanced CKD requiring dialysis, uncontrolled hypertension, current hormone therapy use, or soy intolerance may not benefit.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This Phase 2 randomized trial will evaluate the effect of oral equol versus placebo on vascular function in postmenopausal women with CKD stages 3–4. The study targets improvements in measures of endothelial function and arterial stiffness, areas disrupted by CKD and reduced sex hormone exposure. Participants will be adults aged 50 and older with stable kidney function, low soy intake, and no recent hormone therapy. The trial is sponsored by the University of Colorado, Anschutz Medical Campus, with NHLBI collaboration, and is conducted at a single site in Aurora, Colorado. Safety monitoring will screen for liver enzyme elevations and other adverse events related to soy-derived products.

Why it matters

Potential benefit: If successful, equol could improve vascular function and potentially reduce cardiovascular risk in women with CKD.

How similar studies have gone: Previous work suggests sex-hormone–related vascular effects are modifiable, but this exact equol approach in CKD women is novel and needs evidence of benefit.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Postmenopausal women
* Aged ≥50 years
* CKD stage 3 or 4 (eGFR with the CKD-EPI 2021 race-free equation: 15-59 mL/min/1.73m2; stable renal function in the past 3 months)
* Low habitual intake of soy (soy-related food intake \< 2 times per week assessed by Soy-Specific Food Frequency Questionnaire)
* Weight stable in the prior 3 months (\<2 kg weight change) and willing to remain weight stable throughout the study
* Ability to provide informed consent.

Exclusion Criteria:

* Patients with advanced CKD requiring chronic dialysis
* Uncontrolled hypertension in CKD group (BP \>140/90 mmHg)
* Use of any hormone replacement therapy
* Allergy and/or intolerance to soy or soy-based products
* Aspartate aminotransferase (AST), alanine aminotransferase (ALT), or total bilirubin values 2X upper limit of normal range (upper limit of normal range AST: 117 U/L; ALT: 52 U/L; total bilirubin: 1.3 mg/dL)
* History of breast cancer
* Significant co-morbid conditions with a life expectancy of \< 1 year
* Current tobacco or nicotine use or history of use in the last 12 months
* History of kidney transplant
* History of severe congestive heart failure (i.e., ejection fraction \<35%)
* History of hospitalization within the last month
* Immunosuppressant agents taken in the past 12 months
* Known malignancy

Where it's running

  • University of Colorado Anschutz Medical Campus
    Aurora, Colorado, United States
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.